AR106978A1 - Vacunas felinas de núcleo híbrido - Google Patents

Vacunas felinas de núcleo híbrido

Info

Publication number
AR106978A1
AR106978A1 ARP160103819A ARP160103819A AR106978A1 AR 106978 A1 AR106978 A1 AR 106978A1 AR P160103819 A ARP160103819 A AR P160103819A AR P160103819 A ARP160103819 A AR P160103819A AR 106978 A1 AR106978 A1 AR 106978A1
Authority
AR
Argentina
Prior art keywords
feline
calicivirus
immunogenic composition
fcv
composition according
Prior art date
Application number
ARP160103819A
Other languages
English (en)
Inventor
Hess Jennifer
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of AR106978A1 publication Critical patent/AR106978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una vacuna híbrida para proteger un felino contra enfermedades asociadas a enfermedades respiratorias. La vacuna incluye comúnmente un antígeno felino. También métodos para proteger felinos contra enfermedades asociadas a enfermedades gastrointestinales y respiratorias felinas, que incluyen, entre otras, calicivirus felino, rinotraqueitis felina y panleucopenia felina, y métodos para producir la vacuna felina. Reivindicación 1: Una composición inmunógena no adyuvante caracterizada porque comprende: a) Rinotraqueitis felina; b) Calicivirus felino; c) Calicivirus felino virulento sistémico; y d) Panleucopenia felina. Reivindicación 2: La vacuna o composición inmunógena no adyuvante de acuerdo con la reivindicación 1 caracterizada porque el calicivirus felino y el calicivirus felino virulento sistémico están inactivados. Reivindicación 3: La composición inmunógena no adyuvante de acuerdo con la reivindicación 2, caracterizada porque el calicivirus felino y el calicivirus felino virulento sistémico están inactivados físicamente mediante tratamiento con radiación UV, radiación con rayos X, radiación gamma, congelamiento-descongelamiento y/o calor. Reivindicación 4: La composición inmunógena no adyuvante de acuerdo con la reivindicación 2, caracterizada porque el calicivirus felino y el calicivirus felino virulento sistémico están inactivados químicamente mediante tratamiento con uno o más agentes de inactivación químicos, en donde, con preferencia, uno o más agentes de inactivación químicos se seleccionan del grupo que consiste en b-propiolactona, gluteraldehido, etilenimina, b-etilenimina, etilenimina binaria, acetiletilenimina, ozono y/o formaldehído. Reivindicación 5: La composición inmunógena no adyuvante de acuerdo con la reivindicación 1, caracterizada porque el calicivirus felino se selecciona del grupo que consiste en: FCV-255, FCV-2280, FCV-U1, FCV-Diva, FCV-F9, FCV-F4 y FCV-M8. Reivindicación 8: La composición inmunógena no adyuvante de acuerdo con la reivindicación 6, caracterizada porque el calicivirus virulento sistémico es DD1. Reivindicación 14: La composición inmunógena no adyuvante de acuerdo con la reivindicación 12, caracterizada porque la composición inmunógena no adyuvante está en forma liofilizada. Reivindicación 15: Un método para inmunizar felinos contra enfermedades asociadas a la rinotraqueitis felina, panleucopenia felina y calicivirus, caracterizado porque el método comprende la etapa de administrar a felinos la composición inmunógena de acuerdo con la reivindicación 1.
ARP160103819A 2015-12-14 2016-12-13 Vacunas felinas de núcleo híbrido AR106978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562267005P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
AR106978A1 true AR106978A1 (es) 2018-03-07

Family

ID=57714674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103819A AR106978A1 (es) 2015-12-14 2016-12-13 Vacunas felinas de núcleo híbrido

Country Status (5)

Country Link
US (1) US10188725B2 (es)
EP (1) EP3389706A1 (es)
AR (1) AR106978A1 (es)
TW (1) TW201731526A (es)
WO (1) WO2017106079A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108371710B (zh) * 2018-01-30 2021-09-21 长春西诺生物科技有限公司 猫传染性鼻结膜炎和猫泛白细胞减少症二联疫苗及制备方法
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN111632137B (zh) * 2020-06-19 2022-12-13 郑州爱科生物科技有限公司 猫杯状病毒病、猫传染性鼻气管炎和猫泛白细胞减少症三联疫苗及其制备方法和应用
CN116098994B (zh) * 2022-09-27 2025-08-19 长春西诺生物科技有限公司 猫泛白细胞减少症、猫传染性鼻结膜炎和猫传染性鼻气管炎三联灭活疫苗及制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892627A (en) 1973-06-04 1975-07-01 Rohm & Haas Feline panleukopenia vaccine
US4287178A (en) 1974-03-25 1981-09-01 Pitman-Moore, Inc. Feline rhinotracheitis vaccine and production and use thereof
US3944469A (en) 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US4031204A (en) 1976-03-30 1977-06-21 Norden Laboratories, Inc. Feline viral rhinotracheitis vaccine and combination feline viral rhinotracheitis-calicivirus vaccine prepared therefrom
US4522810A (en) 1982-12-09 1985-06-11 The Regents Of The University Of California Feline calicivirus vaccine
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
US4791062A (en) 1985-02-28 1988-12-13 Diamond Scientific Co. FVR vaccine
US5374424A (en) 1986-10-03 1994-12-20 Miles Inc. Multivalent felv-infected feline vaccine
CA2290906C (en) 1991-06-06 2003-04-01 Stichting Centraal Diergeneeskundig Instituut Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
WO1993001284A1 (en) 1991-07-09 1993-01-21 Cornell Research Foundation, Inc. Recombinant viral vaccine
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
KR100241221B1 (ko) 1991-08-26 2000-03-02 에드워드 콜린스 제임스 돼지 불임 및 호흡기계 중후백신 및 그의 진단법
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
CA2121241C (en) 1991-10-14 2007-12-04 Nicolaas Visser Porcine reproductive respiratory syndrome vaccine and diagnostic
US6010703A (en) 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
ES2165405T3 (es) 1994-04-11 2002-03-16 Akzo Nobel Nv Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv).
EP0732340B1 (en) 1995-03-14 2004-06-09 Akzo Nobel N.V. Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
PT835930E (pt) 1996-10-09 2001-06-29 Akzo Nobel Nv Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6231863B1 (en) 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
AU5329300A (en) 1999-06-10 2001-01-02 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US7309495B2 (en) 2003-03-14 2007-12-18 The Regents Of The University Of California Hemorrhagic feline calicivirus
WO2004083390A2 (en) 2003-03-14 2004-09-30 Regents Of The University Of California Virulent systemic feline calicivirus
WO2005080416A1 (en) 2004-01-20 2005-09-01 Pharmacia & Upjohn Company Llc Feline calicivirus vaccines
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease

Also Published As

Publication number Publication date
US10188725B2 (en) 2019-01-29
TW201731526A (zh) 2017-09-16
EP3389706A1 (en) 2018-10-24
US20170165356A1 (en) 2017-06-15
WO2017106079A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
PE20211545A1 (es) Dosis unitaria de vacuna contra el dengue y administracion de esta
MX2009007399A (es) Proceso y equipo para descontaminar por radiacion un producto tal como un envase que contiene dispositivos medicos.
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
CO6190623A2 (es) Vacuna salmonella
BR112016026721A2 (pt) vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CL2017000625A1 (es) Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
AU2017261705A1 (en) Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
MX389474B (es) Dimetilfumarato y regimenes de vacunacion.
RU2017140856A (ru) Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
RU2021112503A (ru) Поливалентная вакцина против м. hyo и её применение
AR047581A1 (es) Vacunas de calicivirus felino
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
CO2023005611A2 (es) Anticuerpos anti-cd47 novedosos y usos de los mismos
MX2018009048A (es) Extracto de streptococcus uberis como agente inmunogenico.
MX2020006061A (es) Una vacuna para proteccion contra streptococcus suis.
MX2019014354A (es) Metodos para identificar nuevos regimenes de dosificacion.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
CU24686B1 (es) Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b

Legal Events

Date Code Title Description
FB Suspension of granting procedure